<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01070121</url>
  </required_header>
  <id_info>
    <org_study_id>F091007003</org_study_id>
    <nct_id>NCT01070121</nct_id>
  </id_info>
  <brief_title>Treatment Efficacy and Toxicity in Rheumatoid Arthritis Database and Repository</brief_title>
  <acronym>TETRAD</acronym>
  <official_title>Treatment Efficacy and Toxicity in Rheumatoid Arthritis Database and Repository</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>North Shore Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Nebraska</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To stimulate collaborative efforts of federal funding agencies, voluntary health agencies,&#xD;
      professional organizations and industry partners to enable creation of a large, sustainable&#xD;
      database and repository to better understand the molecular basis of treatment and rapidly&#xD;
      accelerate translational research in RA.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rheumatoid arthritis (RA) is the most common inflammatory arthritis, affecting ~1% of the US&#xD;
      population. Severity of RA varies from mild synovitis to joint destruction with associated&#xD;
      disability and increased mortality. Methotrexate (MTX) is the major drug used to treat RA and&#xD;
      the anchor drug for clinical trials of investigational new drugs (INDs) in RA. Eight biologic&#xD;
      agents are currently FDA-approved for RA. No drug is effective in every patient, and there is&#xD;
      great variability in toxicity and price.&#xD;
&#xD;
      The use of concomitant MTX and biologic agents has dramatically improved the outcomes of RA&#xD;
      treatment in the US. This proposal is based on the premise the next major advance needed in&#xD;
      the treatment of RA is not additional drugs, but rather a dramatic improvement in the&#xD;
      efficiency and cost-effectiveness of the use of drugs for individual patients with RA. One of&#xD;
      the hopes for modern medicine is the realization of &quot;personalized&quot; medicine, which allows&#xD;
      accurate, quick prediction of which drug will be the most efficacious, least toxic, and least&#xD;
      expensive for an individual patient.&#xD;
&#xD;
      One of the major obstacles to identifying clinically useful markers of treatment response in&#xD;
      RA is the lack of cohorts with prospectively collected treatment response data coupled with&#xD;
      biological samples. Because of the importance of this issue and the paucity of funding for&#xD;
      such efforts, multiple efforts to establish single institution (using institutional funds) or&#xD;
      multisite cohorts and repositories (typically dependent on private practitioners and&#xD;
      pharmaceutical company support) are planned. To date, there has been no attempt to harmonize&#xD;
      the efforts of the US academic RA research community to create a public resource.&#xD;
&#xD;
      Recognizing that building de novo cohorts within a short time frame is not feasible, our&#xD;
      current proposal will fill a critical need: establishing an infrastructure of academic&#xD;
      investigators to lay the foundation for future collaborative large-scale registries; and&#xD;
      uniting the efforts of many organizations with the common goal of improving care of RA&#xD;
      patients. This project will facilitate future research that will result in significant,&#xD;
      publicly visible improvements in health care. Identifying predictors of treatment response in&#xD;
      RA will lead to rapid, early institution of optimal drugs rather than a &quot;hit or miss&quot;&#xD;
      sequential approach; reduce adverse events; improve patient compliance; and lead to&#xD;
      substantial reduction in the cost of health care. By unifying the efforts of academic&#xD;
      researchers, we can create unique resources, such as a bank of cryopreserved blood cells to&#xD;
      allow sophisticated immunologic research to dissect molecular signals of successful treatment&#xD;
      of RA.&#xD;
&#xD;
      In order to determine the feasibility of this infrastructure for prospectively collecting&#xD;
      data and samples we will enroll a small number of participants (10/site/year for each of 2&#xD;
      years, for a total of 200 participants).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The number of enrolled patients will be used as a measure of success.</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">200</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>RA patients/participants</arm_group_label>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood, red blood cells, white blood cells, plasma, serum, DNA, RNA&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Speciality/referral clinic, Community&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 19 years or older;&#xD;
&#xD;
          2. Diagnosis of RA based on the cumulative presence of at least 4 of 7 ACR Criteria;&#xD;
&#xD;
          3. Willing and able to provide informed consent; and&#xD;
&#xD;
        One of the following:&#xD;
&#xD;
          -  Starting MTX OR&#xD;
&#xD;
          -  Previous or current use of Methotrexate and starting (or switching to) any of the&#xD;
             following medications (with or without MTX)&#xD;
&#xD;
               -  Etanercept&#xD;
&#xD;
               -  Infliximab&#xD;
&#xD;
               -  Adalimumab&#xD;
&#xD;
               -  Rituximab&#xD;
&#xD;
               -  Abatacept&#xD;
&#xD;
               -  Golimumab&#xD;
&#xD;
               -  Certolizumab&#xD;
&#xD;
               -  Tocilizumab&#xD;
&#xD;
        There is no minimum disease activity (number of swollen joints, DAS28, CRP or ESR, etc.)&#xD;
        necessary for enrollment. Treatment decisions are entirely at the discretion of the&#xD;
        treating rheumatologist.&#xD;
&#xD;
        There are no combinations of drugs to be excluded, except those that do not include at&#xD;
        least one of the seven drugs noted above.&#xD;
&#xD;
        Use of corticosteroids (oral, parenteral, intra-articular) is allowed, but must be&#xD;
        recorded.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Concomitant diagnosis of RA and systemic lupus erythematosus, juvenile arthritis, psoriatic&#xD;
        arthritis, hepatitis C infection, current pregnancy or lactation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>S. Louis Bridges, Jr., MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado in Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore Medical Center (LIJ Health System)</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15261</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <study_first_submitted>February 16, 2010</study_first_submitted>
  <study_first_submitted_qc>February 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2010</study_first_posted>
  <last_update_submitted>October 12, 2015</last_update_submitted>
  <last_update_submitted_qc>October 12, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>S. Louis Bridges, MD, PhD</investigator_full_name>
    <investigator_title>Director, Division of Clinical Immunology and Rheumatology</investigator_title>
  </responsible_party>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>RA</keyword>
  <keyword>Autoimmune Disease</keyword>
  <keyword>Muscular Skeletal Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

